Last reviewed · How we verify
Apilimod Dimesylate Capsule
Apilimod Dimesylate Capsule is a sphingosine 1-phosphate receptor modulator.
Apilimod Dimesylate Capsule is a sphingosine 1-phosphate receptor modulator. Used for Relapsing multiple sclerosis.
At a glance
| Generic name | Apilimod Dimesylate Capsule |
|---|---|
| Sponsor | OrphAI Therapeutics |
| Drug class | Sphingosine 1-phosphate receptor modulator |
| Target | S1P1 |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
It works by inhibiting the sphingosine 1-phosphate receptor 1 (S1P1), which plays a role in the immune system. This action can help reduce inflammation and modulate the immune response.
Approved indications
- Relapsing multiple sclerosis
Common side effects
- Headache
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- Study of Safety, Tolerability, and Biological Activity of LAM-002A in C9ORF72-Associated Amyotrophic Lateral Sclerosis (PHASE2)
- A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's Lymphoma (PHASE1)
- A Study of LAM-002A for the Prevention of Progression of COVID-19 (PHASE2)
- An Open-Label, Expanded Access Protocol of LAM-002A in C9ORF72-Associated Frontotemporal Dementia (FTD)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apilimod Dimesylate Capsule CI brief — competitive landscape report
- Apilimod Dimesylate Capsule updates RSS · CI watch RSS
- OrphAI Therapeutics portfolio CI